Latest Breaking News On - Paul achkar - Page 1 : comparemela.com

People with moderate-to-severe ulcerative colitis benefit from a combination of these monoclonal antibodies, compared with induction with either agent alone, according to a new phase 2a study.

United statesNorth carolinaCity ofUnited kingdomBriang feaganJean paul achkarAmerican college of gastroenterologyAlimentiv incWestern universityAmerican collegeScientific meetingFindings through weekMayo scorePaul achkarInflammatory bowel diseaseCleveland clinic